Medicine and Dentistry
Ulcerative Colitis
95%
Patient with Ulcerative Colitis
88%
Organoid
47%
Colonoscopy
37%
Dysplasia
27%
Colon
24%
Neoplasm
24%
Maintenance Therapy
22%
4-Aminosalicylic Acid
21%
Crohn's Disease
19%
Morphology
18%
Intestinal Stem Cell
17%
Inflammatory Bowel Disease
17%
Disease
15%
Intestinal Epithelium
15%
Patient with Crohn's Disease
14%
Short Bowel Syndrome
14%
Medicine
14%
Infliximab
14%
Fecal Microbiota Transplantation
14%
Stomach Cancer
14%
Randomized Controlled Trial
14%
Malignant Neoplasm
13%
Colitis
13%
Mucosa
12%
Signet Ring Cell Carcinoma
12%
Adverse Event
11%
Carcinoma
11%
Irritable Bowel Syndrome
10%
Sigmoid Volvulus
10%
Sigmoid
9%
Small Intestine
9%
Gastrointestinal Distress
8%
Patient with Inflammatory Bowel Disease
8%
Disease Severity
8%
Surgery
8%
Immunomodulating Agent
8%
C Reactive Protein
8%
Infusion
8%
Diagnosis
8%
Diarrhea
8%
Recurrent Disease
8%
Cohort Analysis
7%
Retrospective Cohort Study
7%
Cross Sectional Study
7%
Stem Cell
7%
Central Venous Catheter
7%
Indigo Carmine
7%
Xenotransplantation
7%
Mesalazine
7%
Keyphrases
Ulcerative Colitis
54%
Ulcerative Colitis Patient
24%
Indigo Naturalis
22%
Dysplasia
14%
5-aminosalicylic Acid (5-ASA)
14%
Clinical Relapse
14%
Endoscopic Activity
14%
High-grade Dysplasia
11%
Sigmoid Colon
11%
Mucosa
11%
Sigmoid Volvulus
9%
Water Immersion
9%
Clinical Outcomes
9%
Clinical Characteristics
9%
Colitis-associated Cancer
9%
Mayo Endoscopic Subscore
9%
Risk Factors
9%
Simple Endoscopic Score for Crohn's Disease
8%
Single Center
8%
Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
8%
Mesalamine
8%
Disease Severity
8%
Induction Therapy
7%
Adverse Events
7%
Gastrointestinal Diseases
7%
Water-aided Colonoscopy
7%
Rutgeerts Score
7%
Maintenance Therapy
7%
Ulcerative Colitis-associated Neoplasia
7%
Intestinal Stem Cells
7%
Suppository
7%
Remission Induction
7%
Japanese Nationwide Survey
7%
Hereditary Diffuse Gastric Cancer
7%
Indole Compounds
7%
Japanese Registry
7%
Recent Issues
7%
Stem Cell Dynamics
7%
Redness
7%
Organoid Biobank
7%
Genotype-phenotype Map
7%
Direct Derivation
7%
Alveolosphere
7%
Neoplasia
7%
Calcineurin Inhibitors
7%
Mucosal Concentration
7%
Water Infusion
7%
Intestinal Epithelium
7%
COVID-19
7%
Retrospective Cohort Study
7%
Pharmacology, Toxicology and Pharmaceutical Science
Ulcerative Colitis
100%
Remission
56%
Crohn's Disease
29%
Inflammatory Bowel Disease
24%
Infliximab
21%
Randomized Controlled Trial
15%
Aminosalicylic Acid
14%
Feces microflora
14%
Placebo
11%
Immunomodulating Agent
11%
Mercaptopurine
9%
Intestine Flora
9%
Tumor Necrosis Factor
9%
Calgranulin
8%
C Reactive Protein
8%
Disease
8%
Cross-Sectional Study
7%
Recurrent Disease
7%
Epidermal Growth Factor
7%
5 Acetamidosalicylic Acid
7%
Sigmoid Volvulus
7%
Ustekinumab
7%
Pharmacokinetics
7%
Clostridium Difficile Infection
7%
Prospective Study
7%
Short Bowel Syndrome
7%
Alpha2 Glycoprotein
7%
Leucine
7%
Adverse Event
5%